| Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. | |
| | |
MedLine Citation:
|
PMID: 20336076 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Comparison of the differences between availability of animal-derived surfactant preparations used to treat premature infants is incomplete. The objective of this study was to assess the short-term treatment efficacy of the two most commonly used surfactant preparations in the United States, beractant (100 mg kg(-1) initial and subsequent doses) and poractant alfa (200 mg kg(-1) initial and 100 mg kg(-1) subsequent doses), in very premature, mechanically ventilated infants <30 weeks gestation with respiratory distress syndrome (RDS). STUDY DESIGN: Inborn infants at two institutions, open label, 1:1, randomized controlled trial. Level of respiratory support for first 72 h of life. Morbidities of prematurity observed during the neonatal intensive care unit hospitalization. RESULT: We studied 52 infants 24 0/7 to 29 6/7 weeks gestation; 25 received poractant alfa (27.1±1.6 weeks, birth weight of 930±231 g) and 27 received beractant (26.7±1.7 weeks, P=0.343 and birth weight 900±271 g, P=0.668). Respiratory support for the first 72 h of life was lower in the poractant alfa than beractant group for mean airway pressure (MAP, P=0.003) and respiratory index (MAP × FiO(2), P=0.032). Infants in the poractant alfa group had a greater number of infants extubated at 48 (13/25 vs 6/27, P=0.027) and 72 h (15/25 vs 8/27, P=0.029) than the beractant group. Although the study was not powered to detect morbidities of prematurity, the prevalence of PDA and air leaks was less in the infants treated with poractant alfa than in those treated with beractant. Rates of bronchopulmonary dysplasia (8/23 vs 11/22, P=0.303) or death (2/25 [corrected] vs 5/27, P=0.272) were similar in the infants treated with poractant alfa and beractant, respectively. CONCLUSION: This study suggests significant short-term benefits to the use of the larger initial dose of poractant alfa than beractant in very premature infants with RDS. Further studies involving a larger number of preterm infants are needed to assess long-term effects. |
| | |
Authors:
|
A M Fujii; S M Patel; R Allen; G Doros; C-Y Guo; S Testa |
Related Documents
:
|
18174876 - Viral etiology of acute respiratory infections with cough in infancy: a community-based... 23472766 - Long duration of hyperglycemia in the first 96 hours of life is associated with severe ... 12856986 - Prediction of respiratory distress syndrome by the microbubble stability test on gastri... 8960386 - Susceptibility of exogenous surfactant to phospholipase a2 degradation. 7713046 - Effect of varying protein intake on energy balance, protein balance and estimated weigh... 11070126 - Pena-shokeir type i syndrome with thymic and systemic lymphoid hyperplasia: report of a... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-03-25 |
Journal Detail:
|
Title: Journal of perinatology : official journal of the California Perinatal Association Volume: 30 ISSN: 1476-5543 ISO Abbreviation: J Perinatol Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-29 Completed Date: 2011-01-20 Revised Date: 2012-06-07 |
Medline Journal Info:
|
Nlm Unique ID: 8501884 Medline TA: J Perinatol Country: United States |
Other Details:
|
Languages: eng Pagination: 665-70 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118, USA. Alan.Fujii@bmc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Agents
/
administration & dosage,
therapeutic use* Clinical Protocols Female Humans Infant, Newborn Infant, Premature Infant, Premature, Diseases / drug therapy* Male Phospholipids / administration & dosage, therapeutic use* Prospective Studies Pulmonary Surfactants / administration & dosage, therapeutic use* Respiration, Artificial Respiratory Distress Syndrome, Newborn / drug therapy*, physiopathology Ventilator Weaning |
| Chemical | |
Reg. No./Substance:
|
0/Biological Agents; 0/Phospholipids; 0/Pulmonary Surfactants; 108778-82-1/beractant; 129069-19-8/poractant alfa |
| Comments/Corrections | |
Comment In:
|
J Perinatol. 2010 Oct;30(10):698-9; author reply 698
[PMID:
20877366
]
|
Erratum In:
|
J Perinatol. 2012 May;32(5):395 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of a pediatric ethics committee in the newborn intensive care unit.
Next Document: Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or berac...